Loading…
← CockpitCompetitor Analysis › NUVB Nuvation Bio, Inc. Class AOpen in the cockpit ↗

Nuvation Bio, Inc. Class ANUVBCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops targeted oncology therapies, including an approved treatment for a rare form of lung cancer (Ibtrozi).

Momentum laggard 15
Mkt cap
$1.34B
US dollars, full cap
Free float
72%
of shares outstanding
$/day
$23.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 11.6%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · USD$3.78
1D-3.1%
1W-11.9%
1M-20.8%
3M-44.7%
6M-16.2%
YTD-57.8%
1Y-19.1%
ATR %6.7%
Beta1.70
52w lowhigh61.2% off high

What Nuvation Bio does

Develops targeted oncology therapies, including an approved treatment for a rare form of lung cancer (Ibtrozi).

Its marketed drug Ibtrozi, approved in the US in 2025, came through the 2024 purchase of AnHeart Therapeutics, and product revenue starts from that launch. Oncologists prescribe it for patients whose tumours carry a ROS1 gene change, and it uses cash and launch revenue to fund the rest of its pipeline.

Products and services

  • Ibtrozi/taletrectinib (ROS1+ lung cancer)
  • Oncology pipeline (safusidenib and other targets)

Customers

  • Oncologists/cancer centers

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Targeted oncology therapeutics

What could go right

  • Taletrectinib commercial launch and uptake
  • Pipeline diversification

What could go wrong

  • Competitive ROS1-targeted therapy market
  • Commercial launch execution risk

Moat: none (IP / patents, regulatory licence). Newly approved targeted therapy for a genetically defined lung cancer subtype, in a competitive class.

Headquarters: New York City, US · Founded: 2018 · Employees: 298

Named competitors

Nuvation Bio at a glance

Size Nuvation Bio (NUVB) is a United States Health Care company (Biotechnology) with a market value of $1.34B, the 2052nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.78 on 18 Nov 2026.

Performance Over six months the shares fell 16.2%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 654.2% over the last twelve months (peer median +13.0%); the operating margin is -61.2% (peer median -155.8%).

Valuation It trades at 5.7× enterprise value to sales against a peer median of 15.2× (6th cheapest of 19).

Short interest Short interest is 17.6% of the free float (30 Oct 2026).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026Peer median 80NUVB 79
Six months, rebased to 100: Nuvation Bio against the median of its 20 peers (local-currency closes).

Nuvation Bio financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$202M$62.9M$7.87M$0$0
Revenue growth—+699%———
Gross profit$171M$51.9M$112,000-$222,000-$484,000
EBITDA-$121M-$211M-$167M-$99.6M-$119M
Net income-$136M-$205M-$568M-$75.8M-$104M
Free cash flow-$108M-$174M-$131M-$68.1M-$96.5M
Capital expenditure$1.98M$8.35M$162,000$69,000$370,000
Total debt$468M$213M$8.91M$4.01M$4.26M

Quarterly statements and history in the cockpit →

Nuvation Bio competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%+50%GENBTYRANVAX61854588TSHAANABABSI688105IMCR688765688739MLYSNUVB6-month return →1-month return →
Up and to the right = strong over both horizons. Nuvation Bio is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×250×500×750×GENB688806NVAX4588TSHAABSIQURE688765URGNNUVBRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nuvation Bio is the large dot.

Nuvation Bio competitors and peer comparison

Head to head with its named competitors (NUVB vs RO.SW vs BMY)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Nuvation Bio NUVB$1.34B-16%+654%-61%5.7×n/a
Roche RO.SW$381B+21%-1%31%5.7×1.7%
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%

How Nuvation Bio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nuvation Bio against its 20 peers (data as of 18 Nov 2026)
MeasureNUVBPeer medianRank in peer set
1-month return-20.8%-15.3%5th lowest of 21
6-month return-16.2%-20.3%8th highest of 20
Distance from 52-week high-61.2%-46.5%4th lowest of 21
Revenue growth (TTM)+654.2%+13.0%2nd highest of 18
Operating margin-61.2%-155.8%10th highest of 19
EV / Sales5.7×15.2×6th cheapest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%164.8×n/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%6.8×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a

Questions

Who are Nuvation Bio's main competitors?
Named competitors: Roche (Rozlytrek) (RO.SW), Bristol Myers Squibb (Augtyro) (BMY). The cockpit's measured peer set (industry) also includes Generate Biomedicines (GENB), Tyra Bioscience (TYRA), Zhuhai Trinomab Pharmaceutical (688806.SS), Novavax (NVAX), CanSino Biologics (6185.HK), Intellia Therapeutics (NTLA).
Is Nuvation Bio expensive compared with its peers?
On ev / sales it trades at 5.7× against a peer median of 15.2×, 6th cheapest of 19 in its peer set.
How has Nuvation Bio stock performed?
Over six months to 18 Nov 2026 the shares returned -16.2% against -20.3% for the median peer; over one year -19.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.